首页> 美国卫生研究院文献>BMC Rheumatology >Comparative evaluation of efficacy pharmacodynamics and safety of Hetero’s adalimumab (Mabura® Hetero Biopharma Ltd.) and reference adalimumab (Humira® Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

【2h】

Comparative evaluation of efficacy pharmacodynamics and safety of Hetero’s adalimumab (Mabura® Hetero Biopharma Ltd.) and reference adalimumab (Humira® Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

机译：甲氨蝶呤治疗同时治疗活动性类风湿关节炎患者对Hetero的adalimumab（Mabura®Hetero Biopharma Ltd.）和参比的adalimumab（Humira®Abbvie Inc.）的功效药效学和安全性进行比较评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patient disposition

机译：患者处置

著录项

期刊名称 BMC Rheumatology
作者
Shubhadeep Sinha; Biswadip Ghosh; Syamasis Bandyopadhyay; Firdaus Fatima; Vamsi Krishna Bandi; Pankaj Thakur; Bala Reddy; Sreenivasa Chary; Leela Talluri; Ajay Gupta; Amit Ramchandra Kale; Anil Kumar Gupta; Ashok Kumar P; Diwakar Reddy; Younus Mohammed; Soma Shekar; Sudheer T; Vijay G. Goni; Vishnu Sharma; Vishwanath Yeligod;
展开▼
作者单位

展开▼
年(卷),期 2020(4),-1
年度 2020
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类免疫性疾病;
关键词
Rheumatology; Adalimumab; Methotrexate; Antirheumatic agents;

机译：风湿病;阿达木单抗;甲氨蝶呤;抗风湿药;

相似文献

外文文献
中文文献

1. Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura?, Hetero Biopharma Ltd.) and reference adalimumab (Humira?, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy [J] . Sinha Shubhadeep, Gupta Ajay, Kale Amit Ramchandra, BMC Rheumatology . 2020,第a期

机译：杂种唑（Mabura？，Heterobarma Ltd.）的疗效，药效学和安全性的比较评估，并参考Adalimalab（Humira？，Abbvie Inc.）在伴随甲氨蝶呤治疗的活性类风湿性关节炎患者中
2. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials [J] . Bae Sang-Cheol, Lee Young Ho Clinical rheumatology . 2018,第5期

机译：生物仿生毒率和发起剂Adalimalab与活性类风湿性关节炎患者结合甲氨蝶呤的比较疗效和安全性：随机对照试验的贝叶斯网络荟萃分析
3. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA?) to the reference product (Humira?) in patients with active rheumatoid arthritis [J] . Ahmadreza Jamshidi, Farhad Gharibdoost, Mahdi Vojdanian, Arthritis research & therapy. . 2017,第1期

机译：III期随机，两臂，双盲，平行，主动控制和非劣效性临床试验，用于比较生物仿制药阿达木单抗（CinnoRA？）与参比产品（Humira？）在活动性类风湿病患者中的疗效和安全性关节炎
4. A phase III randomized two-armed double-blind parallel active controlled and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis [O] . Ahmadreza Jamshidi, Farhad Gharibdoost, Mahdi Vojdanian, 2017

机译：III期随机两臂双盲平行主动控制和非劣效性临床试验用于比较生物仿制药阿达木单抗（CinnoRA®）与参比产品（Humira®）在活动性类风湿病患者中的疗效和安全性关节炎
5. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA (R)) to the reference product (Humira (R)) in patients with active rheumatoid arthritis [O] . Jamshidian A., Gharibdoost F., Vojdanian M., 2017

机译：一项III期随机，两臂，双盲，平行，主动控制和非劣效性临床试验，用于比较生物仿制药阿达木单抗（CinnoRA（R））与参比产品（Humira（R））的疗效和安全性。活动性类风湿关节炎患者

Comparative evaluation of efficacy pharmacodynamics and safety of Hetero’s adalimumab (Mabura® Hetero Biopharma Ltd.) and reference adalimumab (Humira® Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

摘要

著录项

相似文献

相关主题

期刊订阅